LANREOTIDE ACETATE (lanreotide acetate) by Ipsen is lanreotide, the active component of lanreotide acetate is an octapeptide analog of natural somatostatin. Approved for well, moderately differentiated, locally advanced and 1 more indications. First approved in 2024.
Drug data last refreshed 19h ago
Lanreotide, the active component of Lanreotide acetate is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Worked on LANREOTIDE ACETATE at Ipsen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo